Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Nippon Shinyaku Co., Ltd. - SIC # 2840 -
Ticker
Exchange
SIC #
Website
Latest Ticker
NPPNY
Over the counter
2840
www.nippon-shinyaku.co.jp
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Nippon Shinyaku Co., Ltd.
ADC Therapeutics Announces ZYNLONTA® Updates in Japan
- Oct 29th, 2026 5:30 am
Nippon Shinyaku (TSE:4516) Stock Looks Fairly Valued At Current Levels
- Oct 17th, 2026 8:09 pm
NS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 BIO's Tadekinig alfa in the U.S.
- Jul 30th, 2026 7:03 am
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa
- Jul 30th, 2026 12:33 am
Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
- Jun 26th, 2026 7:01 am
Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
- Jun 26th, 2026 4:23 am
NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children's Hospital
- Jun 23rd, 2026 5:13 am
All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement – CAPR Stock Jumps 6%
- Jun 17th, 2026 8:24 am
Regenxbio Shares Rise After Positive Duchenne Trial Results
- May 14th, 2026 8:09 am
Capricor Lawsuit Puts Duchenne Therapy Launch Plans And Valuation In Focus
- May 13th, 2026 6:18 am
Capricor Therapeutics Q1 Earnings Call Highlights
- May 12th, 2026 4:08 pm
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- May 12th, 2026 2:05 pm
Regenxbio Inc (RGNX) Q3 2025 Earnings Call Highlights: Strong Financial Position and Strategic ...
- Nov 6th, 2025 12:08 pm
Scroll